文献速递其他结缔组织病血管炎自身炎症与 IgG4 相关病

阿尼鲁单抗:治疗ADA2缺陷症的潜在选择

Anifrolumab, a potential treatment for ADA2 deficiency.
PubMed 文献 · RMD Open · 2026-07-06

本文报告一例26岁女性,最初诊断为系统性红斑狼疮,因低丙种球蛋白血症、B细胞减少及抗dsDNA消失等非典型演变,经基因检测确诊为ADA2缺陷症。该患者接受阿尼鲁单抗治疗后迅速达到临床缓解并显著减少糖皮质激素用量,全血细胞中I型干扰素评分降低,TNFα和IL-6表达持续低于抗TNFα治疗时。这是首次报道阿尼鲁单抗成功用于ADA2缺陷症。

要点

  • SLE伴低丙种球蛋白血症等非典型表现应警惕ADA2缺陷症。
  • 阿尼鲁单抗可快速诱导ADA2缺陷症临床缓解并减少激素用量。
  • 阿尼鲁单抗治疗时I型干扰素评分降低,支持其用于干扰素病谱系疾病。

核心结论

  • 阿尼鲁单抗可能成为ADA2缺陷症的有效治疗选择,但需进一步研究验证。

研究设计与样本

  • 本文为单例病例报告,描述一名26岁女性ADA2缺陷症患者的诊治经过及治疗前后实验室指标变化。

主要发现

  • 患者因SLE非典型演变(低丙种球蛋白血症、中度B细胞减少、抗dsDNA消失)经基因检测确诊为ADA2缺陷症(CECR1/ADA2纯合5类错义变异)。
  • 阿尼鲁单抗治疗后患者迅速达到临床缓解并显著减少糖皮质激素用量。
  • 与抗TNFα治疗相比,阿尼鲁单抗治疗期间患者全血细胞I型干扰素评分降低,TNFα和IL-6表达水平持续较低。

临床怎么用

  • 对SLE伴低丙种球蛋白血症等非典型表现者,应考虑ADA2缺陷症并进行基因检测。
  • 在ADA2缺陷症中可考虑试用阿尼鲁单抗,尤其存在I型干扰素通路激活证据时。

局限性

  • 证据仅来自单例病例报告,无法推广至所有ADA2缺陷症患者。
  • 阿尼鲁单抗在ADA2缺陷症中的疗效和安全性需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adenosine deaminase 2 deficiency (DADA2) is an inborn error of immunity leading to systemic vasculitis, haematological manifestations, immune deficiency and/or autoimmunity. We report the case of a 26-year-old female with an initial diagnosis of systemic lupus erythematosus (SLE). However, atypical evolution patterns for SLE (hypogammaglobulinaemia, moderate B-cell lymphopenia, disappearance of anti-dsDNA) led to the identification of a homozygous class 5 missense variant of CECR1/ADA2, thus to a final diagnosis of DADA2. Strikingly, the patient was treated with anifrolumab (an anti-interferon alpha receptor 1 antibody) that rapidly induced clinical remission and significant corticosteroid tapering. Consistently, we show a lower type I interferon (IFN-I) score and a persistently low tumour necrosis factor α (TNFα) and IL-6 expression levels in whole blood cells of the patient during anifrolumab compared to anti-TNFα. Altogether, this case (1) illustrates the challenging diagnosis of DADA2 (SLE with hypogammaglobulinaemia) and (2) reinforces DADA2 as a disease at the border with type I interferonopathies. Besides, we report here, to our knowledge, the first description of a successful use of anifrolumab in DADA2, paving the way for further studies to validate this therapeutic approach.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Vincenti L, Sormani J, Belot A, et al. Anifrolumab, a potential treatment for ADA2 deficiency. RMD Open. 2026. PMID: 42409574. doi:10.1136/rmdopen-2025-006569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。